Immuno-Biological Laboratories Co., Ltd. (TYO:4570)

Japan · Delayed Price · Currency is JPY

1,007.00

+4.00 (0.40%)

Oct 26, 2026, 3:30 PM JST

Market Cap	9.38B +109.8%
Revenue (ttm)	1.08B +13.5%
Net Income	369.00M +43.0%
EPS	39.62 +43.0%
Shares Out	9.31M
PE Ratio	25.42
Forward PE	n/a
Dividend	7.50 (0.74%)
Ex-Dividend Date	Mar 30, 2026

Volume	58,100
Open	1,003.00
Previous Close	1,003.00
Day's Range	994.00 - 1,049.00
52-Week Range	464.00 - 3,820.00
Beta	-0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About TYO:4570

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents internationally. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and supports research services on Alzheimer’s disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA test kits, antibodies, synthetic peptides, cell culture-related reagents, and contract services such as antibody pr... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1982

Employees 54

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4570

Full Company Profile

Financial Performance

In fiscal year 2026, TYO:4570's revenue was 1.00 billion, an increase of 3.61% compared to the previous year's 969.00 million. Earnings were 329.00 million, an increase of 32.13%.

Financial Statements